B. Riley Wealth Advisors Inc. Invests $776,000 in AstraZeneca PLC $AZN

B. Riley Wealth Advisors Inc. bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,110 shares of the company’s stock, valued at approximately $776,000.

A number of other hedge funds have also recently made changes to their positions in AZN. NewSquare Capital LLC boosted its position in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. Richardson Financial Services Inc. grew its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares during the period. FSA Wealth Management LLC raised its holdings in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after purchasing an additional 376 shares during the period. VSM Wealth Advisory LLC purchased a new position in AstraZeneca during the second quarter worth approximately $33,000. Finally, Maseco LLP acquired a new stake in AstraZeneca in the second quarter valued at approximately $34,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AZN shares. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Morgan Stanley reiterated an “overweight” rating and set a $103.00 price target on shares of AstraZeneca in a report on Wednesday, December 3rd. Jefferies Financial Group began coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating on the stock. HSBC reaffirmed a “buy” rating and set a $108.00 price target on shares of AstraZeneca in a report on Wednesday, December 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Trading Down 0.2%

Shares of AZN stock opened at $91.35 on Wednesday. The stock has a market cap of $283.32 billion, a P/E ratio of 30.35, a P/E/G ratio of 1.70 and a beta of 0.32. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $94.01. The business has a fifty day simple moving average of $87.26 and a 200-day simple moving average of $79.50.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.AstraZeneca’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.08 EPS. On average, analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.